drug

sebetralstat

Marketedupdated 3mo ago

by $KALV KalVista Pharmaceuticals, Inc.

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying sebetralstat

—Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstatavailable
—Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstatapproved for marketing

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 3, 2030

~3.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

Jan 26, 2039formulationUS 11234939
Dec 25, 2037compositionUS 11230537
Jun 23, 2037method-of-use (U-4223)US 11739068
Nov 26, 2035compositionUS 10364238
Nov 26, 2035method-of-use (U-4223)US 10611758
Nov 26, 2035compositionUS 11001578
Nov 26, 2035compositionUS 11084809
Nov 26, 2035method-of-use (U-4223)US 11198691

FDA exclusivities (1)

Jul 3, 2030NCENew Chemical Entity (5y)3.9y

News(4)

‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.
fiercebiotech · 6d ago
Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail
Despite a Phase 3 miss, Gossamer Bio is full steam ahead for its lung disease asset, pointing to previous “review issues” at the FDA as one of the reasons to continue development.
biospace · 24d ago
Chiesi to buy KalVista in $1.9B deal for rare disease drug
The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.
biopharma_dive · 3mo ago
STAT+: A patent win for Pfizer and BridgeBio
A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout
stat · 3mo ago

Data sources

ClinicalTrials.gov

last refreshed 1m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(4)

‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery

BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.

fiercebiotech · 6d ago

Gossamer regains rights to lung disease asset from Chiesi after Phase 3 fail

Despite a Phase 3 miss, Gossamer Bio is full steam ahead for its lung disease asset, pointing to previous “review issues” at the FDA as one of the reasons to continue development.

biospace · 24d ago

Chiesi to buy KalVista in $1.9B deal for rare disease drug

The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.

biopharma_dive · 3mo ago

STAT+: A patent win for Pfizer and BridgeBio

A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout

stat · 3mo ago

sebetralstat

all catalysts(0)

Trials studying sebetralstat

Patent cliff

patents (8)

FDA exclusivities (1)

News(4)

Report a data issue

comments(0)

sebetralstat

all catalysts(0)

Trials studying sebetralstat

Patent cliff

patents (8)

FDA exclusivities (1)

News(4)

Report a data issue

comments(0)